Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population

References

• Jacobson DR, Alexander AA, Tagoe C, et al. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171–174. doi: 10.3109/13506129.2015.1051219.
   PubMed Web of Science ®Google Scholar
• Buxbaum J, Alexander A, Koziol J, et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) studies. Am Heart J. 2010;159(5):864–870. doi: 10.1016/j.ahj.2010.02.006.
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Garg S, Drazner MH, et al. Clinical implications of the amyloidogenic V122I transthyretin variant in the general population. J Card Fail. 2022;28(3):403–414. doi: 10.1016/j.cardfail.2021.09.015.
   PubMed Web of Science ®Google Scholar
• Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. JAMA. 2019;322(22):2191–2202. doi: 10.1001/jama.2019.17935.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–172. doi: 10.1016/j.jacc.2016.03.596.
   PubMed Web of Science ®Google Scholar
• Parcha V, Malla G, Irvin MR, et al. Association of transthyretin Val122Ile variant with incident heart failure among black individuals. JAMA. 2022;327(14):1368–1378. doi: 10.1001/jama.2022.2896.
   PubMed Web of Science ®Google Scholar
• Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. doi: 10.1161/CIRCULATIONAHA.118.038169.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Sinha A, Zheng Y, Nannini D, et al. Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged black adults: Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA Cardiol. 2020;6(6):1–5. doi: 10.1001/jamacardio.2020.6623.
   PubMed Web of Science ®Google Scholar
• Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly Black Americans. N Engl J Med. 2015;372(1):21–29. doi: 10.1056/NEJMoa1404852.
   PubMed Web of Science ®Google Scholar
• Coniglio AC, Segar MW, Loungani RS, et al. Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in black adults. JACC Heart Fail. 2022;10(2):129–138. doi: 10.1016/j.jchf.2021.09.006.
   PubMed Web of Science ®Google Scholar
• Hendren NS, Roth LR, Grodin JL. Disease-specific biomarkers in transthyretin cardiac amyloidosis. Curr Heart Fail Rep. 2020;17(3):77–83. doi: 10.1007/s11897-020-00457-z.
   PubMed Web of Science ®Google Scholar
• Saef J, Martyn T, Ives L, et al. Predictive modeling to assess pretest probability of transthyretin gene variants based on demographic information. Circ Heart Fail. 2023;16(4):e009908.
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Tabbarah M, Nowalk MP, et al. Racial differences in beliefs about genetic screening among patients at inner-city neighborhood health centers. J Natl Med Assoc. 2006;98(3):370–377.
   PubMed Web of Science ®Google Scholar
• Suther S, Kiros GE. Barriers to the use of genetic testing: a study of racial and ethnic disparities. Genet Med. 2009;11(9):655–662. doi: 10.1097/GIM.0b013e3181ab22aa.
   PubMed Web of Science ®Google Scholar
• Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459–2462. doi: 10.1126/science.1062245.
   PubMed Web of Science ®Google Scholar
• Victor RG, Haley RW, Willett DL, et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93(12):1473–1480. doi: 10.1016/j.amjcard.2004.02.058.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–2512. doi: 10.1001/jama.2010.1768.
   PubMed Web of Science ®Google Scholar
• Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46(4):352–356. doi: 10.1038/ng.2901.
   PubMed Web of Science ®Google Scholar
• Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension. 2005;46(1):124–129. doi: 10.1161/01.HYP.0000169972.96201.8e.
   PubMed Web of Science ®Google Scholar
• Kwanbunjan K, Panprathip P, Phosat C, et al. Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural Thais with high type 2 diabetes risk. BMC Endocr Disord. 2018;18(1):26. doi: 10.1186/s12902-018-0254-2.
   PubMed Web of Science ®Google Scholar
• Griffin JM, Rosenthal JL, Grodin JL, et al. ATTR amyloidosis: current and emerging management strategies: JACC: Cardio Oncology state-of-the-art review. JACC CardioOncol. 2021;3(4):488–505. doi: 10.1016/j.jaccao.2021.06.006.
   PubMedGoogle Scholar
• Greve AM, Christoffersen M, Frikke-Schmidt R, et al. Association of low plasma transthyretin concentration with risk of heart failure in the general population. JAMA Cardiol. 2021;6(3):258–266. doi: 10.1001/jamacardio.2020.5969.
   PubMed Web of Science ®Google Scholar
• Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid. 2008;15(4):255–261. doi: 10.1080/13506120802525285.
   PubMed Web of Science ®Google Scholar
• Kelly JW. Mechanisms of amyloidogenesis. Nat Struct Biol. 2000;7(10):824–826. doi: 10.1038/82815.
   PubMedGoogle Scholar
• Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439–1447. doi: 10.1093/eurheartj/ehz905.
   PubMed Web of Science ®Google Scholar
• Buxbaum J, Anan I, Suhr O. Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid. 2010;17(2):83–85. doi: 10.3109/13506129.2010.483118.
   PubMed Web of Science ®Google Scholar
• Noy N, Li L, Abola MV, et al. Is retinol binding protein 4 a link between adiposity and cancer? Horm Mol Biol Clin Investig. 2015;23(2):39–46. doi: 10.1515/hmbci-2015-0019.
   PubMedGoogle Scholar
• Hyung SJ, Deroo S, Robinson CV. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol. 2010;5(12):1137–1146. doi: 10.1021/cb100144v.
   PubMed Web of Science ®Google Scholar
• Kontorovich AR, Abul-Husn NS. Retinol binding protein 4 as a screening biomarker for hereditary TTR amyloidosis in African American adults with TTR V142I. J Card Fail. 2021;27(9):1020–1022. doi: 10.1016/j.cardfail.2021.05.009.
   PubMed Web of Science ®Google Scholar
• Arvanitis M, Simon S, Chan G, et al. Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. Amyloid. 2017;24(Suppl. 1):120–121. doi: 10.1080/13506129.2017.1295371.
   PubMedGoogle Scholar
• Arvanitis M, Koch CM, Chan GG, et al. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model. JAMA Cardiol. 2017;2(3):305–313. doi: 10.1001/jamacardio.2016.5864.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10(1):109. doi: 10.1186/s13023-015-0326-6.
   PubMed Web of Science ®Google Scholar